• 1

    Wongsrichanalai C, Murray CK, Gray M, Miller RS, McDaniel P, Liao WJ, Pickard AL, Magill AJ, 2003. Co-infection with malaria and leptospirosis. Am J Trop Med Hyg 68 :583–585.

    • Search Google Scholar
    • Export Citation
  • 2

    Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM, 2003. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 3 :757–771.

    • Search Google Scholar
    • Export Citation
  • 3

    Levett PN, 2001. Leptospirosis. Clin Microbiol Rev 14 :296–326.

  • 4

    Hospenthal DR, Murray CK, 2003. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob Agents Chemother 47 :2646–2648.

    • Search Google Scholar
    • Export Citation
  • 5

    Murray CK, Hospenthal DR, 2004. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob Agents Chemother 48 :1548–1552.

    • Search Google Scholar
    • Export Citation
  • 6

    National Committee for Clinical Laboratory Standards (NC-CLS), 1997. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Fourth Edition. Approved Standard. NCCLS document M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards.

  • 7

    Lell B, Kremsner PG, 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46 :2315–2320.

  • 8

    Krudsood S, Buchachart K, Chalermrut K, Charusabba C, Treeprasertsuk S, Haoharn O, Duangdee C, Looareesuwan S, 2002. A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug falciparum malaria. Southeast Asian J Trop Med Public Health 33 :525–531.

    • Search Google Scholar
    • Export Citation
  • 9

    Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J, 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28 :74–81.

    • Search Google Scholar
    • Export Citation
  • 10

    Bajani MD, Ashford DA, Bragg SL, Woods CW, Aye T, Spiegel RA, Plikaytis BD, Perkins BA, Phelan M, Levett PN, Weyant RS, 2003. Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol 41 :803–809.

    • Search Google Scholar
    • Export Citation

 

 

 

 

SUSCEPTIBILITY OF LEPTOSPIRA SEROVARS TO ANTIMALARIAL AGENTS

View More View Less
  • 1 Infectious Disease Service, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas

Leptospirosis has recently been described to cause concomitant infection with malaria. Only doxycycline has proven to have chemoprophylactic and therapeutic efficacy for both malaria and leptospirosis. To assess whether other traditional antimalarial agents have antileptospiral activity, we performed broth microdilution susceptibility testing of 16 Leptospira serovars (6 species/14 serogroups) to various agents. Artemisinin, atovaquone, chloroquine, mefloquine, primaquine, proguanil, pyrimethamine, sulfadoxine, quinine, quinidine, and combinations of atovaquone/proguanil and pyrimethamine/sulfadoxine all had a 90% minimum inhibitory concentration (MIC90) > 25 μg/mL (the upper limit of testing). The only agents identified with the potential to treat both infections other than doxycycline (MIC90 = 1.56 μg/mL) were azithromycin (MIC90 = 0.002 μg/mL) and clindamycin (MIC90 = 0.2 μg/mL).

Save